Skip to Main Content

An official website of the United States government

View 0 Studies Requested

Trial Summary

About CDAS Project, PI, Publications: Validation of Serum Markers for early Detection of Ovarian Cancer

Datasets


Site: Ovary

Inclusion Criteria:

  • Females
  • No Prior History of Any Cancer
  • No Report of Bilateral Oophorectomy
  • Exclude LMPs and Reported Cancers

Matching Factors:

  • Age at Serum Draw (5 years)
  • Year of Serum Draw

Match Ratio: 4:1 for general controls, 2:1 for controls who ever had an elevated CA-125, and 2:1 for controls who have a family history of breast or ovarian cancer

Match Technique: Frequency matching only non-cases as controls.


Analytes:

  • Apolipoprotein A-I
  • Beta-2-microglobulin
  • Cancer Antigen 125
  • Cancer Antigen 15-3
  • Cancer Antigen 19-9
  • Cancer Antigen 72-4
  • Connective Tissue-Activating Peptide III
  • Eotaxin
  • Epidermal Growth Factor Receptor
  • Hepcidin-25
  • Human Epididymis Protein 4
  • Insulin-like Growth Factor 2
  • Insulin-like Growth Factor Binding Protein 2
  • Inter-alpha-trypsin inhibitor heavy chain H4
  • Kallikrein-6
  • Leptin
  • Macrophage Migration Inhibitory Factor
  • Matrix Metalloproteinase-3
  • Matrix Metalloproteinase-7
  • Mesothelin
  • Osteopontin
  • Prolactin
  • Secretory Leukocyte Protease Inhibitor
  • Soluble Vascular Cell Adhesion Molecule
  • Spondin 2
  • Transferrin
  • Transthyretin
  • V-set domain-containing T-cell activation inhibitor 1

Number of Cases: 119

Number of Controls: 952